<div class=”itemVideoEmbedded”><a href=”http://www.cannabisfn.com/quote/?ticker=CANLF”>Cannabis Technologies Inc.</a> (<span id=”qmStockQuote”><span class=”qmjssymbol”>CANLF</span> <span class=”qmjsdata”>0,40</span> <span class=”qmjsdataup”>6,35 {92d3d6fd85a76c012ea375328005e518e768e12ace6b1722b71965c2a02ea7ce}</span></span>), a leading innovator of technology and science within the cannabis sector, was recently highlighted in a Canadian TV (“CTV”) interview discussing the benefits of medical marijuana. As an ovarian cancer survivor, Ms. Shuman has become a leading advocate for the ongoing legalization of cannabis and research conducted by companies in the space, particularly companies like Cannabis Technologies that are working to reduce the time to commercialize cannabis based therapies.</div>
<p>Cannabis Technologies Inc. is a biopharmaceutical drug discovery and development company focused on cannabinoids that has been dubbed by many as the “Junior GW” in the space. By leveraging its proprietary platform, the company’s management team aims to identify new bioactive compounds within the marijuana plant that interact with specific genes to produce meaningful clinical outcomes.</p>
<p>According to Chief Science Officer Sazzad Hossain, the proprietary platform provides the necessary tools to isolate and identify chemical compounds in marijuana in months rather than years. The company will use the platform to isolate compounds targeting specific diseases and conditions and then outsource the early-stage research and trials to get to Phase I as quickly and inexpensively as possible.</p>
<p>Initially, the company plans to focus on the $12 billion ocular disease market, including the $5.7 billion glaucoma market, where its CTI-085 is preparing to undergo Phase I clinical trials shortly. In addition to this area, management has expressed interest in larger markets like pain and inflammation, as well as orphan diseases classified by the FDA like cancers and metabolic diseases.</p>
<p>Just like <a href=”http://www.cannabisfn.com/quote/?ticker=GWPH”>GW Pharmaceuticals plc</a> (<span id=”qmStockQuote”><span class=”qmjssymbol”>GWPH</span> <span class=”qmjsdata”>88,95</span> <span class=”qmjsdataup”>2,70 {92d3d6fd85a76c012ea375328005e518e768e12ace6b1722b71965c2a02ea7ce}</span></span>), the company also operates a breeding and cultivation division that’s responsible for creating the medicines in-house. The proprietary phyto-stock produced by the division sets it apart from competitors that rely on third-parties to manufacture their treatments, since the fully-integrated operations both lower costs and increase quality.</p>
<p>Shares of Cannabis Technologies were trading even in early trading on Tuesday, July 22, 2014.</p>
- Our Company
- Our Clients
- Mining and Mineral Exploration
- Arctic Star Exploration (ADD:TSXV)
- Canada Silver Cobalt Works Inc. (CCW:TSXV)
- Glen Eagle Resources (GER:tsxv)
- Granada Gold Mine Inc. (GGM:tsxv)
- Mosaic Minerals Corp. (MOC:CSE)
- Newlox Gold Ventures Corp. (LUX:CSE)
- Rio Silver Inc. (RYO:tsxv)
- Rover Metals Corp. (ROVR:tsxv)
- San Marco Resources (SMN:tsxv)
- Sonoro Gold Corp (SGO:tsxv)
- St-Georges Eco-Mining (SX:CSE)
- TRU Precious Metals (TRU:tsxv)
- Usha Resources Ltd. (USHA:tsxv)
- Biotech and Life Science
- Technology and FinTech
- Mining and Mineral Exploration
- News
- Contact Us